Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Talis Biomedical (NASDAQ:TLIS) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
Talis Biomedical beat estimated earnings by 9.59%, reporting an EPS of $-0.66 versus an estimate of $-0.73.
Revenue was down $1.97 million from the same period last year.
Last quarter the company missed on EPS by $0.33 which was followed by a 6.08% drop in the share price the next day.
Here's a look at Talis Biomedical's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.68 | -0.73 | -0.80 | -1.18 |
EPS Actual | -1.01 | -0.98 | -1.01 | -1.25 |
Revenue Estimate | 800K | 600K | 700K | 650K |
Revenue Actual | 257K | 796K | 572K | 3.19M |
To track all earnings releases for Talis Biomedical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TLIS